International Prostate Cancer Update 2019

The Gold Standard for Bladder Cancer Detection

Neal D. Shore, MD, discusses the benefits of using blue light cystoscopy (BLC) in adjunct with white light cystoscopy (WLC) in the diagnosis and treatment of bladder cancers. He then reviews the body of evidence evaluating the accuracy of BLC in detecting significant tumors and briefly compares BLC and narrow band imaging.

Read More

Timing of ADT with Chemotherapy in 2019

Thomas E. Keane, MD, reviews the data supporting and opposing the advancement of chemotherapy into the metastatic castration-sensitive prostate cancer (mCSPC) disease state. He then discusses a current trial introducing chemotherapy in patients prior to androgen deprivation therapy (ADT).

Read More

Second Opinion Diagnosis in Prostate Pathology

Francisco G. La Rosa, MD, discusses how poor preparation of biopsy and prostatectomy specimens, as well as pathologists’ misreadings, can lead to significant discrepancies in the diagnosis of prostate cancer. He emphasizes the importance of reevaluation by in-house urologic pathologists of all outside specimens before evaluating treatment options for patients.

Read More

Future Options for Urology Practice Ownership

Gary M. Kirsh, MD, discusses the challenges that independent urology practices face from complexities in the constantly-evolving healthcare industry. He then describes the benefits of adopting configurations of independent urology groups in which physicians have equity ownership.

Read More
Loading

Join the GRU Community

- Why Join? -